# A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

> **NCT02161757** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1207 (actual)

## Conditions studied

- Uncontrolled Asthma

## Interventions

- **BIOLOGICAL:** Tralokinumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02161757
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-13
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-07-18
- **Target enrollment:** 1207 (ACTUAL)
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161757, "A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02161757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*